United States: PTAB Upholds Lialda Patent Over Kyle Bass IPR Challenge

The USPTO Patent Trial and Appeal Board (PTAB) has issued a final written decision upholding Shire's Lialda® patent over the Inter Partes Review (IPR) challenge brought by Kyle Bass and his Coalition for Affordable Drugs. The decision underscores that obviousness is not established simply because each feature of a claim is found somewhere in the prior art where there is inadequate evidence of a motivation to arrive at the claimed invention as a whole.

The Lialda Patent At Issue

The patent at issue was Shire's U.S. Patent 6,773,720, which is the only Orange Book-listed patent for Lialda®, which is approved for treating Crohn's disease and ulcerative colitis. The patent relates to a pH-independent controlled release formulation of mesalazine (also known as 5-amino-salicylic acid or 5-ASA). Independent claim 1 recites:

  1. Controlled-release oral pharmaceutical compositions containing as an active ingredient 5-amino-salicylic acid, comprising:

    1. an inner lipophilic matrix consisting of substances selected from the group consisting of unsaturated and/or hydrogenated fatty acid, salts, esters or amides thereof, fatty acid mono-, di- or triglycerids, waxes, ceramides, and cholesterol derivatives with melting points below 90°C, and wherein the active ingredient is dispersed both in said the lipophilic matrix and in the hydrophilic matrix;
    2. an outer hydrophilic matrix wherein the lipophilic matrix is dispersed, and said outer hydrophilic matrix consists of compounds selected from the group consisting of polymers or copolymers of acrylic or methacrylic acid, alkylvinyl polymers, hydroxyalkyl celluloses, carboxyalkyl celluloses, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, and natural or synthetic gums;
    3. optionally other excipients; wherein the active ingredient is present in an amount of 80 to 95% by weight of the total composition, and wherein the active ingredient is dispersed both in the lipophilic matrix and in the hydrophilic matrix.

The PTAB Decision

The PTAB decision was rendered in Coalition for Affordable Drugs II LLC v. Cosmo Technologies, IPR2015-00988, and is the first final written decision issued in an IPR proceeding brought by Kyle Bass and the Coalition for Affordable Drugs (CFAD). Controversial petitioners aside, the decision also deserves attention because it underscores an important hurdle to establishing obviousness before the PTAB—proving a motivation to combine the asserting teachings of the cited prior art references.

Obviousness Of Pharmaceutical Formulation Patents

Formulation claims like those at issue in this case are generally thought to be susceptible to an obviousness attack because many of the basic principles of formulating pharmaceutical products (e.g., how to achieve controlled release) and the components used are known in the art. Thus, patentability often is based on a lack of motivation to combine known components in the manner recited in the claims, lack of a reasonable expectation of success in achieving a product with the desired properties, and/or unexpected results achieved by the claimed formulation. The PTAB's analysis in this case shows that the motivation prong can play a key role in an IPR proceeding.

CFAD relied on two references for its obviousness challenge:

  • Groenendaal was cited as the primary reference, and disclosed "controlled-release oral compositions comprising biologically active substances," including 5-ASA.
  • Leslie was cited as a secondary reference that disclosed components used in the claimed formulation.

CFAD argued that one of skill in the art would have been motivated to improve the formulations of Groenendaal by combining them with elements taught in Leslie. (Read more about the IPR petition in this post here.)

The patentee countered CFAD's arguments by arguing that this was not a case of selecting "known options" from a "finite number of identified, predictable solutions." In this regard, the patentee argued that CFAD's cited art gave little indication as to which components were critical and which of the many possible choices were likely to be successful. Rather, according to the patentee, the cited art supplied numerous options that could be formulated into numerous types of controlled release dosage forms, but did not provide any motivation or reveal a reason why a person of ordinary skill in the art would have been motivated to "improve" the Groenendaal's 5-ASA compositions.

Ultimately, the PTAB agreed with the patentee. The PTAB was unconvinced by CFAD's assertions that manufacturing costs or concerns over "pH-dependent and time-dependent drug delivery approaches" would have been sufficient to motivate a person of ordinary skill in the art to combine the various aspects of the prior art as required to arrive at the claimed formulation. The PTAB also found that CFAD had failed to explain why one would have sought to improve Groenendaal's 5-ASA formulations in the specific manner claimed in the '720 patent when there were many other options for achieving pH-independent controlled release.

This holding underscores that even if individual claim elements are taught in the prior art, a petitioner must explicitly and compelling establish a motivation to combine. As the PTAB reminded the parties in this case:

To the extent that it is a close call, it is noteworthy that the burden of persuasion is on the Petitioner.

More Decisions On Motivation

The Federal Circuit recently affirmed a similar PTAB decision in Apotex, Inc. v. Wyeth, LLC, 2015-1871 (Fed. Cir. August 16, 2016) (appeal of IPR2014-00115). The patent at issue in Apotex was directed to a formulation of tigecycline, a known tetracycline antibiotic, that prevents degradation of the drug.

In the IPR, Apotex cited prior art that disclosed a nearly identical formulation of mincocyline (another tetracycline antibiotic) and prior art that discussed minocycline and tetracycline degradation pathways. Nevertheless, the PTAB upheld the validity of the challenged claims, because Apotex had failed to show why a person of ordinary skill in the art would have been motivated to substitute tigecycline for minocycline in the prior art formulations.

In affirming the PTAB decision, the Federal Circuit found that even though tigecycline and minocycline are both tetracycline antibiotics and tigecycline could, theoretically, be substituted into the prior art formulation, "there is not necessarily a motivation to substitute one antibiotic for a structurally related one...and there is nothing in the record here to show that the substitution would solve any other problem."

These decisions underscore the importance of the motivation prong of an obviousness case, especially in front of the PTAB where the APJ's are more likely than a district court jury to scrutinize technical arguments. Establishing what a person of ordinary skill in the art could have done is not sufficient. To establish obviousness a petitioner must show what such a person would have done. A patent owner defending against obviousness may be able to prevail by showing that a a person of ordinary skill in the art would have been faced with many options, with no particular reason to make the selections required to arrive at the claimed subject matter, and/or no reasonable expectation that making those selections would be advantageous.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.